Skip to main content

Advertisement

SpringerLink
Log in

ALCAM is indirectly modulated by miR-125b in MCF7 cells

  • Research Article
  • Published:
Tumor Biology

Abstract

MicroRNA (miRNA) deregulation is associated with various cancers. Among an expanding list of cancer-related miRNAs, deregulation of miR-125b has been well documented in many cancers including breast. Based on current knowledge, miR-125b is considered to be a tumor suppressor in breast cancers. While important messenger RNA (mRNA) targets have been defined for miR-125b, here, we aimed to further investigate direct/indirect consequences of miR-125b expression in breast cancer cells by using a transcriptome approach. Upon miR-125b expression, a total of 138 cancer-related genes were found to be differentially expressed in breast cancer cells. While only a few of these were predicted to be direct mRNA targets, majority of the gene expression changes were potentially downstream and indirect effects of miR-125b expression. Among these, activated leukocyte antigen molecule (ALCAM) mRNA and protein levels were found to be highly significantly increased upon miR-125b expression. Given the tumor suppressor role of miR-125b in our model system, upon silencing of ALCAM expression, cell proliferation rate re-increased in miR-125b-expressing cells. While ALCAM’s possible context-dependent roles are not clear in breast cancer, a diverse expression pattern of ALCAM mRNA was detected in a panel of breast cancer patient samples. Differentially expressed/regulated cancer-related genes upon miR-125b expression along with the significant increase of ALCAM are of future interest to understand how deregulated expression of miR-125b may have a tumor suppressor role in breast and other cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Bartel D. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.

    Article  CAS  PubMed  Google Scholar 

  2. Erson A, Petty E. MicroRNAs in development and disease. Clin Genet. 2008;74:296–306.

    Article  CAS  PubMed  Google Scholar 

  3. Erson AE, Petty EM. MiRNAs and cancer: new research developments and potential clinical applications. Cancer Biol Ther. 2009;8:2317–22.

    Article  CAS  PubMed  Google Scholar 

  4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065–70.

    Article  CAS  PubMed  Google Scholar 

  5. Calin G, Croce C. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  CAS  PubMed  Google Scholar 

  6. Iorio M, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007;67:8699–707.

    Article  CAS  PubMed  Google Scholar 

  7. Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297:1901–8.

    Article  CAS  PubMed  Google Scholar 

  8. Bousquet M, Quelen C, Rosati R, Mansat-De Mas V, La Starza R, Bastard C, et al. Myeloid cell differentiation arrest by mir-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation. J Exp Med. 2008;205:2499–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009;15:5473–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Selcuklu SD, Yakicier MC, Erson AE. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer Genet Cytogenet. 2009;189:15–23.

    Article  CAS  PubMed  Google Scholar 

  11. Mattie M, Benz C, Bowers J, Sensinger K, Wong L, Scott G, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5:24.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Scott G, Goga A, Bhaumik D, Berger C, Sullivan C, Benz C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA mir-125a or mir-125b. J Biol Chem. 2007;282:1479–86.

    Article  CAS  PubMed  Google Scholar 

  13. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. Mir-125b targets ARID3B in breast cancer cells. Cell Struct Funct. 2012;37:27–38.

    Article  CAS  PubMed  Google Scholar 

  14. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. Mir-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer ;2010.

  15. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, et al. Mir-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71:3552–62.

    Article  CAS  PubMed  Google Scholar 

  16. Huang L, Luo J, Cai Q, Pan Q, Zeng H, Guo Z, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2f3. Int J Cancer. 2011;128:1758–69.

    Article  CAS  PubMed  Google Scholar 

  17. Ozek NS, Tuna S, Erson-Bensan AE, Severcan F. Characterization of microRNA-125b expression in MCF7 breast cancer cells by ATR-FTIR spectroscopy. Analyst. 2010;135:3094–102.

    Article  PubMed  Google Scholar 

  18. Kauffmann A, Gentleman R, Huber W. Arrayqualitymetrics—a bioconductor package for quality assessment of microarray data. Bioinformatics. 2009;25:415–6.

    Article  CAS  PubMed  Google Scholar 

  19. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Smyth GK, Michaud J, Scott HS. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005;21:2067–75.

    Article  CAS  PubMed  Google Scholar 

  21. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–84.

    Article  CAS  PubMed  Google Scholar 

  22. Falcon S, Gentleman R. Using gostats to test gene lists for go term association. Bioinformatics. 2007;23:257–8.

    Article  CAS  PubMed  Google Scholar 

  23. Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM, Erson AE. Usp32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome. 2010;21:388–97.

    Article  CAS  PubMed  Google Scholar 

  24. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time pcr experiments. Clin Chem U S. 2009;55:611–22.

    Article  CAS  Google Scholar 

  25. Gur-Dedeoglu B, Konu O, Bozkurt B, Ergul G, Seckin S, Yulug IG. Identification of endogenous reference genes for qrt-pcr analysis in normal matched breast tumor tissues. Oncol Res. 2009;17:353–65.

    Article  PubMed  Google Scholar 

  26. Fleige S, Walf V, Huch S, Prgomet C, Sehm J, Pfaffl MW. Comparison of relative mrna quantification models and the impact of RNA integrity in quantitative real-time RT-PCR. Biotechnol Lett. 2006;28:1601–13.

    Article  CAS  PubMed  Google Scholar 

  27. Wang J, Gu Z, Ni P, Qiao Y, Chen C, Liu X, et al. NF-kappab p50/p65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res. 2011;39:6440–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jannie KM, Stipp CS, Weiner JA. ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells. PLoS One. 2012;7:e39330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Degen WG, van Kempen LC, Gijzen EG, van Groningen JJ, van Kooyk Y, Bloemers HP, et al. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am J Pathol. 1998;152:805–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Ofori-Acquah SF, King JA. Activated leukocyte cell adhesion molecule: a new paradox in cancer. Transl Res. 2008;151:122–8.

    Article  CAS  PubMed  Google Scholar 

  31. Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Wilczak W, Lebok P. Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: a TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncol Rep. 2014.

  32. Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins. 2000;40:420–8.

    Article  CAS  PubMed  Google Scholar 

  33. Swart GW. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol. 2002;81:313–21.

    Article  CAS  PubMed  Google Scholar 

  34. Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010;7:231–43.

    CAS  PubMed  Google Scholar 

  35. Graham K, de las Morenas A, Tripathi A, King C, Kavanah M, Mendez J, et al. Gene expression in histologically normal epithelium from breast cancer patients and from cancer-free prophylactic mastectomy patients shares a similar profile. Br J Cancer. 2010;102:1284–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jezierska A, Olszewski WP, Pietruszkiewicz J, Olszewski W, Matysiak W, Motyl T. Activated leukocyte cell adhesion molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit. 2006;12:BR245–56.

    CAS  PubMed  Google Scholar 

  37. Tan F, Mosunjac M, Adams AL, Adade B, Taye O, Hu Y, et al. Enhanced down-regulation of ALCAM/CD166 in African-American breast cancer. BMC Cancer. 2014;14:715.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Burkhardt M, Mayordomo E, Winzer KJ, Fritzsche F, Gansukh T, Pahl S, et al. Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol. 2006;59:403–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A. 2008;105:1608–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Dusek RL, Bascom JL, Vogel H, Baron S, Borowsky AD, Bissell MJ, et al. Deficiency of the P53/P63 target PERP alters mammary gland homeostasis and promotes cancer. Breast Cancer Res. 2012;14:R65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Jacobson A, Cunningham JL. Connective tissue growth factor in tumor pathogenesis. Fibrogenesis Tissue Repair. 2012;5 Suppl 1:S8.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We would like to thank Dr. Q. Fan and Prof. Ofori-Acquah for sharing ALCAM promoter constructs, Dr. J. Weiner for ALCAM shRNA construct, and Serkan Tuna and Cansaran Saygılı for technical assistance. CS, MTA, and DS were supported by funding from Science Foundation Ireland, IRCSET, and Cancer Research Ireland. This research was funded by METU internal funds and partially by TUBITAK 108S381.

Conflicts of interest

None

Author information

Author notes

  1. S. Duygu Selcuklu

    Present address: Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA

  2. Mark T. A. Donoghue

    Present address: Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY, 11724, USA

  3. Shiva Akhavantabasi

    Present address: Department of Molecular Biology and Genetics, Yeni Yuzyil University, Istanbul, Turkey

  4. Aysegul Sapmaz

    Present address: Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, Netherlands

Authors and Affiliations

  1. Department of Biology, M.E.T.U., Dumlupınar Bulvarı No: 1, Cankaya, 06800, Ankara, Turkey

    H. Begum Akman, Shiva Akhavantabasi, Aysegul Sapmaz & A. Elif Erson-Bensan

  2. Genetics and Biotechnology Laboratory, School of Natural Sciences, National University of Ireland, Galway, Ireland

    S. Duygu Selcuklu & Mark T. A. Donoghue

  3. Genetics and Biotechnology Laboratory, Plant & AgriBiosciences Research Centre (PABC), School of Natural Sciences, National University of Ireland, Galway, Ireland

    Charles Spillane

  4. Department of Molecular Biology and Genetics, Acibadem University, Istanbul, Turkey

    M. Cengiz Yakicier

Authors
  1. H. Begum Akman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Duygu Selcuklu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark T. A. Donoghue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shiva Akhavantabasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aysegul Sapmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Charles Spillane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Cengiz Yakicier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Elif Erson-Bensan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Elif Erson-Bensan.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supp. Table 1

Breast cancer patient panel information. (PDF 126 kb)

Supp. Table 2, 3

Significantly up-regulated (n=68) and down-regulated genes (n=70) in MCF7-125b cells. (PDF 265 kb)

Supp. Fig. 1

Volcano plot represents the relationship between fold change and statistical significance. X-axis represents the log2 Fold Change between MCF7-EV and MCF7-miR-125b cells. The vertical axis represents the Log Odds (B-Statistic). (PDF 810 kb)

Supp. Fig. 2

A. T47D cells stably transfected with miR-125b or with EV (empty vector, pSUPER). miR-125b expression levels were normalized to U6 expression. Two independent experiments were performed with triplicate replicates. The Student t-test was used for analyzing the data. Transfected cells were polyclonally selected. B. Cell proliferation assay (MTT) was performed in T47D cells, transfected with precursor miR-125b and Empty Vector (EV) as control. Experiment was performed with 4 replicates for each sample. All OD570 values were divided into that of day 1 for both miR-125b and EV cells. 10,000 cells were initially seeded into each well of 96-well cell culture plates and four replicates were used for each sample. C. Seven fold induction of ALCAM expression in MCF7-EV and MCF7-125b cells. Bands were quantified using ImageJ. D. ALCAM protein levels were detectable in T47D-EV cells and no apparent increase was detected upon miR-125b expression. (PDF 256 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akman, H.B., Selcuklu, S.D., Donoghue, M.T.A. et al. ALCAM is indirectly modulated by miR-125b in MCF7 cells. Tumor Biol. 36, 3511–3520 (2015). https://doi.org/10.1007/s13277-014-2987-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2987-5

Keywords

Search

Navigation